Skip to main content

Table 4 Adverse effects of liposomal irinotecan.

From: Cancer nanomedicine: a review of recent success in drug delivery

  Most common grade 3–4 adverse events
PEPO2 Irinotecan Docetaxel
N % n % n %
Anaemia 2 4.5 2 4.5 3 6.8
Neutropaenia 5 11.4 7 15.9 2 2.6
Thrombocytopenia 1 2.3 1 2.3 0 0
Febrile neutropenia 3 6.8 5 11.3 2 2.6
Diarrhoea 12 27.3 8 18.2 1 2.3
Nausea 5 11.4 2 4.6 0 0
Vomiting 2 4.6 6 13.6 3 6.8
Anorexia 3 6.8 3 6.8 0 0
Fatigue 2 4.6 1 2.3 1 2.3
  1. Most common grade 3–5 adverse events observed in a phase II study of liposomal irinotecan (PEP02), comprised of a liposomal irinotecan, irinotecan, and docetaxel arm